

# Fact Sheet

**Bio<sub>2</sub>XyTran<sup>®</sup> Inc.**

Tissue Regeneration For Life

BioXyTran, Inc. is a biopharmaceutical company focused on the development and commercialization of first-in-class treatments for hypoxic conditions and necrosis prevention. Our initial targeted medical conditions are ischemic stroke. The company's lead product candidate, **BXT-25**, will be tested as a potent resuscitative agent to treat cerebrovascular accidents. The product is based on a new molecule, initially developed for blood substitution. The company plans to submit an Investigational New Drug (IND) to the FDA and enter into clinical trials.



## Product Portfolio

Drug	Indication	Advantages
BXT-25	Cerebrovascular accidents (ischemic stroke)	Resuscitative agent, low-viscosity, with small molecular size (<1/5000 of a red blood cell) can flow through clot
BXT-251	Organ preservation	Protection agent (medical device approval)
BXT-252	Wound healing	Oxygen-carrying molecule, small size, can penetrate tissues by diffusion
BXT-253	Heart Attack	Angioplasty and Cardiac Revascularization
BXT-254	Cancer	Human Nasopharyngeal Carcinoma (with 2 Gy Rad)

## **BXT-25: Market Opportunity**

The Global Stroke Diagnostics and Therapeutics Market was valued at \$20.5 billion in 2014, and is expected to reach nearly \$34.4 billion by 2022, growing at a CAGR of 6.68% from 2014 to 2022.

Other indications include traumatic brain injury (TBI), anti-necrosis, wound healing, transfusion therapy (blood loss), and therapeutic treatment for anemia, bringing the total current market opportunity to well over \$50 billion annually

# Advantages

- **Experienced management:** BioXyTran, Inc.'s management team has a successful track record in the biotech and pharmaceutical arena, with decades of collective experience.
- **Focus on novel therapeutic opportunities:** To date, only a few drugs have been approved for ischemic stroke, wound healing and TBI. There is currently no effective way to treat necrosis or hypoxia. Oxygen Therapy Inc. is positioned to become a major player in this field of unmet medical needs.
- **Balanced profile:** Our two leading products for humans position Oxygen Therapy Inc. as a leader in two large and growing hypoxia-treatment markets.
- **Drugs are differentiated formulations:** Our lead drug product candidates are well-differentiated and designed to treat complications of hypoxia.
- **Intellectual property and market protection:** The Company owns a key patent and is developing a robust intellectual property portfolio of patent applications and trademarks.

## Leadership and management

**David Platt, CEO** (Ph.D., Chemical Engineering) is a pioneer in designing drugs made from natural polymers, and has more than 30 years of experience in the development of therapeutic drugs. He is the inventor or co-inventor on a number of patents, primarily in the field of carbohydrate chemistry. Founder of three publicly traded companies (NASDAQ: IGGI, AMEX: PRW, NASDAQ: GALT).

**Elena Chekhova, CSO** (Ph.D., Process Systems Engineering) has over 10 years of experience in the life sciences industry in business development and project management services

**Ola Soderquist, CFO** (CPA, CMA, MBA) is an entrepreneur, and business executive, with proven abilities in both established organizations and start-up ventures.

Revised 11/30/2017

## Development Plans

- Preparation for scale-up and manufacturing GLP/GMP - 12 months, \$3.15M
- Toxicity in animals for Investigational New Drug application - 16 month, \$1.50M
- Phase I (safety)/II (proof of concept) clinical trials - 18 months, 3.50M.
- General & Administrative \$1.85M

## Drug Characteristics

- Delivers oxygen instantly followed by infusion
- Long shelf life—3 years in liquid form at room temperature
- Longer shelf life in dry form
- Non-immunogenic
- Small molecule (<1/5000th the size of a red blood cell)
- Low viscosity

## Contact:

**David Platt, PhD/CEO**

[david.platt@bioxytraninc.com](mailto:david.platt@bioxytraninc.com)

(617)-510-2539

[www.bioxytraninc.com](http://www.bioxytraninc.com)

Any statements in this fact sheet about future expectations, plans and prospects for the Company constitute forward-looking statements as defined in the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on management's current expectations and are subject to a number of factors and uncertainties, which could cause actual results to differ materially from those described in such statements. More information about those risks and uncertainties is contained and discussed in the Company's most recent quarterly or annual report and in the Company's other reports filed with the Securities and Exchange Commission. The forward-looking statements represent the Company's views as of the date of this fact sheet and should not be relied upon to represent the Company's views as of a subsequent date. While the Company anticipates that subsequent events may cause the Company's views to change, the Company disclaims any obligation to update such forward-looking statements.